Corbus Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union Pharmaceutical Investing
Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA Biotech Investing
Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease Biotech Investing
ChroMedX Provides 2016 Development Summary and Reports on Recent Warrant Exercise and Expiration Medical Device Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
